Edition:
India

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

155.81USD
19 Jan 2018
Change (% chg)

$5.25 (+3.49%)
Prev Close
$150.56
Open
$150.81
Day's High
$156.18
Day's Low
$150.81
Volume
100,779
Avg. Vol
85,234
52-wk High
$156.18
52-wk Low
$95.21

Latest Key Developments (Source: Significant Developments)

Ligand Pharma And Glenmark Pharma Enter Into License Agreement
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS.LIGAND PHARMACEUTICALS - ‍ UNDER LICENSE, GLENMARK WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND MULTISPECIFIC ANTIBODIES​.LIGAND PHARMACEUTICALS INC - ‍GLENMARK WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​.LIGAND - ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, REGULATORY MILESTONE PAYMENTS, AMONG OTHERS, FOR PRODUCTS INCORPORATING OMNIAB ANTIBODY​.  Full Article

Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS.SEES FY 2017 ADJUSTED EARNINGS PER SHARE $3.13 TO $3.16.SEES FY 2017 REVENUE ABOUT $140 MILLION.  Full Article

Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Ligand Pharmaceuticals Inc :Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​.Ligand Pharmaceuticals Inc - ‍currently believes potential royalty revenue growth for 2018 could be in range of 15% to 25% over that of full year 2017​.Ligand Pharmaceuticals Inc - ‍full-year 2018 corporate gross margin is expected to be in range of 94% to 96%​.  Full Article

Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Ligand Pharmaceuticals Inc :Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​.Ligand Pharmaceuticals Inc - ‍Ligand could receive commercial revenue from shipment of Captisol to Meridian for clinical and commercial activities​.Ligand Pharmaceuticals - ‍co granting Meridian exclusive right to use Captisol in Meridian's development and commercialization of a Captisol.Ligand Pharmaceuticals says ‍could potentially receive payments associated with certain licenses, royalties and milestone payments -SEC filing​.  Full Article

Ligand Q3 adjusted earnings per share $0.69
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Ligand Pharmaceuticals Inc ::Ligand reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.69.Q3 earnings per share $0.36.Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $134 million to $136 million.Ligand Pharmaceuticals Inc - ‍total revenues for Q3 of 2017 were $33.4 million, compared with $21.6 million for same period in 2016​.Ligand Pharmaceuticals Inc - ‍ligand updates guidance for 2017 revenue to be between $134 and $136 million​.Ligand Pharmaceuticals Inc - ‍adjusted earnings per diluted share is now expected to be between $2.95 and $3.00 for 2017 ​.Q3 revenue view $30.9 million -- Thomson Reuters I/B/E/S.FY 2017 earnings per share view $2.95, revenue view $134.5 million -- Thomson Reuters I/B/E/S.  Full Article

Ligand Q2 adjusted earnings per share $0.50
Thursday, 4 Aug 2016 

Ligand Pharmaceuticals Inc : Q2 adjusted earnings per share $0.50 . Q2 GAAP loss per share $0.28 . Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S . Sees FY 2016 revenue $115 million to $119 million . Sees FY 2016 adjusted earnings per share $3.41 to $3.46 .FY2016 earnings per share view $3.30, revenue view $116.6 million -- Thomson Reuters I/B/E/S.  Full Article

Ligand announces licensing agreement with Nucorion Pharmaceuticals
Friday, 29 Jul 2016 

Ligand Pharmaceuticals Inc : Ligand announces multi-program LTP technology licensing agreement with nucorion pharmaceuticals . Newly-Formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets . Eligible to receive milestone payments as well as royalties ranging from 5% to 9% on net sales of products developed by Nucorion under agreement .Ligand announces multi-program LTP technology licensing agreement with Nucorion pharmaceuticals.  Full Article

Ligand enters into Omniab platform license agreement with Gilead Sciences
Friday, 8 Jul 2016 

Ligand Pharmaceuticals Inc : Ligand enters into Omniab® platform license agreement with Gilead Sciences . Gilead will be responsible for all costs related to programs .Ligand is eligible to receive annual platform access payments, milestone payments and royalties.  Full Article

Ligand Pharmaceuticals Inc gives FY 2016 and FY 2017 guidance
Wednesday, 4 May 2016 

Ligand Pharmaceuticals Inc:Says that including the effects of synthetic royalty acquisition from CorMatrix, Ligand now expects FY 2016 total revenues to be between $115 million and $119 million.Says this guidance assumes about $1 million of revenue from the CorMatrix assets in 2016.Projects FY 2016 adjusted EPS to be in the range of $3.41 to $3.46, which includes about $0.04 of incremental EPS contribution from the acquisition.Says for FY 2017, Ligand expects total revenues to exceed $160 million with adjusted EPS of more than $5.03.Says this guidance assumes about $2 million of revenue from the CorMatrix assets in 2017, and about $0.08 of incremental EPS contribution from the acquisition.  Full Article

Ligand Pharmaceuticals Inc receives FDA Approval of EVOMELA(tm) (melphalan) for Injection
Tuesday, 15 Mar 2016 

Ligand Pharmaceuticals Inc:Approval from the U.S. Food and Drug Administration (FDA) of EVOMELA(tm) (melphalan) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM.  Full Article

BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS